Recent advances in ocular drug delivery

Amongst the various routes of drug delivery, the field of ocular drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientist. Recent research has focused on the characteristic advantages and limitations of the various drug delivery systems, and further research will be required before the ideal system can be developed. Administration of drugs to the ocular region with conventional delivery systems leads to short contact time of the formulations on the epithelium and fast elimination of drugs. This transient residence time involves poor bioavailability of drugs which can be explained by the tear production, non-productive absorption and impermeability of corneal epithelium. Anatomy of the eye is shortly presented and is connected with ophthalmic delivery and bioavailability of drugs. In the present update on ocular dosage forms, chemical delivery systems such as prodrugs, the use of cyclodextrins to increase solubility of various drugs, the concept of penetration enhancers and other ocular drug delivery systems such as polymeric gels, bioadhesive hydrogels, in-situ forming gels with temperature-, pH-, or osmotically induced gelation, combination of polymers and colloidal systems such as liposomes, niosomes, cubosomes, microemulsions, nanoemulsions and nanoparticles are discussed. Novel ophthalmic delivery systems propose the use of many excipients to increase the viscosity or the bioadhesion of the product. New formulations like gels or colloidal systems have been tested with numerous active substances by in vitro and in vivo studies. Sustained drug release and increase in drug bioavailability have been obtained, offering the promise of innovation in drug delivery systems for ocular administration. Combining different properties of pharmaceutical formulations appears to offer a genuine synergy in bioavailability and sustained release. Promising results are obtained with colloidal systems which present very comfortable conditions of use and prolonged action.

[1]  L. Gan,et al.  Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. , 2009, International journal of pharmaceutics.

[2]  Rania M. Hathout,et al.  Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. , 2005, International journal of pharmaceutics.

[3]  P. Sado,et al.  Ophthalmic drug delivery systems—Recent advances , 1998, Progress in Retinal and Eye Research.

[4]  A. Ludwig,et al.  The use of mucoadhesive polymers in ocular drug delivery. , 2005, Advanced drug delivery reviews.

[5]  Uday B Kompella,et al.  Recent advances in ophthalmic drug delivery. , 2010, Therapeutic delivery.

[6]  H. Tsuneoka,et al.  Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. , 2011, Investigative ophthalmology & visual science.

[7]  P. J. Murphy,et al.  Carbomer and Sodium Hyaluronate Eyedrops for Moderate Dry Eye Treatment , 2008, Optometry and vision science : official publication of the American Academy of Optometry.

[8]  G. Spedalieri,et al.  Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. , 2002, Biomaterials.

[9]  M. Samaha,et al.  Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment , 2009, Drug development and industrial pharmacy.

[10]  Pushpa Mishra,et al.  Sustained Ocular Drug Delivery from a Temperature and pH Triggered Novel In Situ Gel System , 2007, Drug delivery.

[11]  D. Attwood,et al.  In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. , 2001, International journal of pharmaceutics.

[12]  Y. Shimomura,et al.  Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-β-cyclodextrin in rabbit. , 2010, Biological & pharmaceutical bulletin.

[13]  S. Benita,et al.  Ocular delivery of cyclosporin A. II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A , 2001 .

[14]  A. Makky,et al.  Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. , 2010, Molecular pharmaceutics.

[15]  M. Aqil,et al.  Evaluation of Carbopol-Methyl Cellulose Based Sustained-Release Ocular Delivery System for Pefloxacin Mesylate Using Rabbit Eye Model , 2006, Pharmaceutical development and technology.

[16]  S. Benita,et al.  Influence of Emulsion Droplet Surface Charge on Indomethacin Ocular Tissue Distribution , 2000, Pharmaceutical development and technology.

[17]  G. Yener,et al.  Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives , 2007, International journal of nanomedicine.

[18]  H. Sasaki,et al.  Different Effects of Absorption Promoters on Corneal and Conjunctival Penetration of Ophthalmic Beta-Blockers , 1995, Pharmaceutical Research.

[19]  Siling Wang,et al.  Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. , 2009, International journal of pharmaceutics.

[20]  C. Sébastian,et al.  A new long acting ophthalmic formulation of carteolol containing alginic acid. , 2000, International journal of pharmaceutics.

[21]  P. Edman Biopharmaceutics of Ocular Drug Delivery , 1992 .

[22]  Robert Gurny,et al.  PATENT LITERATURE REVIEW OF OPHTHALMIC INSERTS , 1995 .

[23]  P. Maincent,et al.  Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. , 1993, Pharmaceutical research.

[24]  D. Aggarwal,et al.  Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. , 2005, International journal of pharmaceutics.

[25]  S. Seal,et al.  Nanoceria particles prevent ROI-induced blindness. , 2008, Advances in experimental medicine and biology.

[26]  P. Couvreur,et al.  Cationic Vectors in Ocular Drug Delivery , 2004, Journal of drug targeting.

[27]  Y. Lo,et al.  Characterization of pilocarpine‐loaded chitosan/Carbopol nanoparticles , 2006, The Journal of pharmacy and pharmacology.

[28]  M. Espina,et al.  Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. , 2006, Journal of pharmaceutical sciences.

[29]  P. Maincent,et al.  [Ways to improve ocular bioavailability for topical applications]. , 2000, Journal francais d'ophtalmologie.

[30]  E. Stefánsson,et al.  Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. , 2007, Acta ophthalmologica Scandinavica.

[31]  R. Cavalli,et al.  Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. , 2002, International journal of pharmaceutics.

[32]  A. El-Kamel,et al.  Environmentally Responsive Ophthalmic Gel Formulation of Carteolol Hydrochloride , 2006, Drug delivery.

[33]  John W. Shell Ophthalmic drug delivery systems , 1984 .

[34]  S. Jain,et al.  Polymeric pseudolatices bearing pilocarpine for controlled ocular delivery. , 1992, Journal of microencapsulation.

[35]  Weisan Pan,et al.  Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. , 2006, International journal of pharmaceutics.

[36]  F. Ahmad,et al.  Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[37]  L. Laroche,et al.  [Treatment of dry eye syndrome with lacrimal gel: a randomized multicenter study]. , 1991, Journal francais d'ophtalmologie.

[38]  S. Saraf,et al.  Cubosomes: an overview. , 2007, Biological & pharmaceutical bulletin.

[39]  A. El-Kamel In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. , 2002, International journal of pharmaceutics.

[40]  V. H. Lee,et al.  Influence of Preparation Conditions on Acyclovir-Loaded Poly-d,l-Lactic Acid Nanospheres and Effect of PEG Coating on Ocular Drug Bioavailability , 2003, Pharmaceutical Research.

[41]  J. Carlfors,et al.  Rheological evaluation of Gelrite in situ gels for ophthalmic use. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[42]  M. Ghorab,et al.  Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. , 2007, International journal of pharmaceutics.

[43]  R. Gurny,et al.  A water-soluble prodrug of cyclosporine A for ocular application: a stability study. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[44]  P. J. Murphy,et al.  Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[45]  I. Antal,et al.  Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. , 2007, International journal of pharmaceutics.

[46]  Eaga Chandra Mohan,et al.  Preparation and Evaluation of In-Situ-Gels for Ocular Drug Delivery , 2009 .

[47]  A. Mahmoud,et al.  Nanoemulsion as a Potential Ophthalmic Delivery System for Dorzolamide Hydrochloride , 2009, AAPS PharmSciTech.

[48]  C. Allaire,et al.  Ocular hypotensive efficacy and safety of once daily carteolol alginate , 2001, British Journal of Ophthalmology.

[49]  S. P. Srinivas,et al.  Use of fluorometry in assessing the efficacy of a cation-sensitive gel as an ophthalmic vehicle: comparison with scintigraphy. , 1992, Journal of pharmaceutical sciences.

[50]  J W Shell,et al.  Pharmacokinetics of topically applied ophthalmic drugs. , 1982, Survey of ophthalmology.

[51]  F. Manvi,et al.  In situ-forming hydrogels for sustained ophthalmic drug delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[52]  M. Alonso,et al.  Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. , 2001, International journal of pharmaceutics.

[53]  L. Gan,et al.  Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability , 2010, Acta Pharmacologica Sinica.

[54]  K. Hosny Preparation and Evaluation of Thermosensitive Liposomal Hydrogel for Enhanced Transcorneal Permeation of Ofloxacin , 2009, AAPS PharmSciTech.

[55]  L. Gan,et al.  Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. , 2010, International journal of pharmaceutics.

[56]  Dina Fathalla,et al.  Liposomes as an ocular delivery system of fluconazole: in‐vitro studies , 2010, Acta ophthalmologica.

[57]  J. Romanet,et al.  [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. , 2003, Journal francais d'ophtalmologie.

[58]  J. C. Robinson Ocular anatomy and physiology relevant to ocular drug delivery , 1993 .

[59]  Siling Wang,et al.  Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. , 2009, The Journal of pharmacy and pharmacology.

[60]  S. S. Imam,et al.  Stimuli-sensitive hydrogels: A novel ophthalmic drug delivery system , 2010, Indian journal of ophthalmology.

[61]  A. Mitra,et al.  Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. , 2002, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[62]  A. Vila,et al.  Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. , 2006, Investigative ophthalmology & visual science.

[63]  S. Fialho,et al.  New vehicle based on a microemulsion for topical ocular administration of dexamethasone , 2004, Clinical & experimental ophthalmology.

[64]  G. Abdelbary,et al.  Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery , 2008, AAPS PharmSciTech.

[65]  D. Aggarwal,et al.  Role of cyclodextrins in ophthalmics. , 2004, Current drug delivery.

[66]  D. Aggarwal,et al.  Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. , 2007, International journal of pharmaceutics.

[67]  Rania M. Hathout,et al.  Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies , 2007, AAPS PharmSciTech.

[68]  Philippe Maincent,et al.  Moyens d'amélioration de la biodisponibilité pour la voie topique , 2000 .

[69]  Jiasheng Tu,et al.  Preparation and ocular pharmacokinetics of ganciclovir liposomes , 2007, The AAPS Journal.

[70]  Indu Pal Kaur,et al.  Ocular Preparations: The Formulation Approach , 2002, Drug development and industrial pharmacy.

[71]  P. Amin,et al.  Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[72]  K. Hosny Ciprofloxacin as Ocular Liposomal Hydrogel , 2010, AAPS PharmSciTech.

[73]  D. Aggarwal,et al.  Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[74]  D. Shastri,et al.  Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery , 2010, Journal of young pharmacists : JYP.

[75]  Alejandro Sánchez,et al.  Chitosan Nanoparticles as New Ocular Drug Delivery Systems: In Vitro Stability, in Vivo Fate, and Cellular Toxicity , 2005, Pharmaceutical Research.

[76]  José Juan Escobar-Chávez,et al.  Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[77]  E. Stefánsson,et al.  Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. , 2002, Acta ophthalmologica Scandinavica.

[78]  Amélie Bochot,et al.  Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. , 2008, Experimental eye research.

[79]  S. Benita,et al.  Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[80]  J. Pandit,et al.  Ion-Activated In Situ Gelling Systems for Sustained Ophthalmic Delivery of Ciprofloxacin Hydrochloride , 2003, Drug delivery.

[81]  E. Stefánsson,et al.  Comparison of topical 0.7% dexamethasone–cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[82]  B Pietzyk,et al.  Degradation of phosphatidylcholine in liposomes containing carboplatin in dependence on composition and storage conditions. , 2000, International journal of pharmaceutics.

[83]  W. Pan,et al.  Preparation and Evaluation of Sustained Ophthalmic Gel of Enoxacin , 2005, Drug development and industrial pharmacy.

[84]  A. A. Yasseen,et al.  Nanoceria have no genotoxic effect on human lens epithelial cells , 2010, Nanotechnology.

[85]  P. Maincent,et al.  Poly(ε-Caprolactone) Nanocapsules in Carteolol Ophthalmic Delivery , 1993, Pharmaceutical Research.